Kinnate Biopharma (KNTE) News Today → Do This Today BEFORE Biden Wins in November (From Stansberry Research) (Ad) Free KNTE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineKNTE Kinnate Biopharma Inc.seekingalpha.com - April 5 at 12:24 AMmarketbeat.com - April 3 at 6:06 AMKinnate Biopharma Inc. (NASDAQ:KNTE) Receives Average Recommendation of "Hold" from Analystsmarketbeat.com - April 1 at 6:14 AMKinnate Biopharma Inc. (NASDAQ:KNTE) Short Interest Down 43.6% in Marchmarketbeat.com - March 28 at 10:30 AMCitigroup Inc. Increases Position in Kinnate Biopharma Inc. (NASDAQ:KNTE)marketbeat.com - March 22 at 4:34 AMKINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEbusinesswire.com - March 13 at 11:49 AMKinnate Biopharma (KNTE) to Release Quarterly Earnings on Wednesdaymarketbeat.com - March 12 at 7:35 AMKinnate Biopharma Inc. (NASDAQ:KNTE) Given Consensus Recommendation of "Hold" by Brokeragesmarketbeat.com - March 7 at 5:47 AMKinnate Biopharma Inc. (NASDAQ:KNTE) Stake Increased by Citigroup Inc.marketbeat.com - March 4 at 4:34 AMKinnate Biopharma sells rights of exarafenib to Pierre Fabre laboratoriesmsn.com - March 1 at 9:12 PMKinnate Biopharma Sells Exarafenib To Pierre Fabre Laboratories - Quick Factsmarkets.businessinsider.com - March 1 at 2:49 PMKinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratoriesprnewswire.com - March 1 at 8:35 AMKinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratoriesglobenewswire.com - March 1 at 8:30 AMAcadian Asset Management LLC Raises Holdings in Kinnate Biopharma Inc. (NASDAQ:KNTE)marketbeat.com - February 29 at 5:45 AMStifel Nicolaus Boosts Kinnate Biopharma (NASDAQ:KNTE) Price Target to $2.59marketbeat.com - February 26 at 10:18 AMKINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEbusinesswire.com - February 19 at 11:03 AMKinnate Biopharma just downgraded at William Blair, here's whyrealmoney.thestreet.com - February 17 at 3:06 PMPrivate equity firms who hold 45% of Kinnate Biopharma Inc. (NASDAQ:KNTE) gained 11%, institutions profited as wellfinance.yahoo.com - February 17 at 10:04 AMALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.prnewswire.com - February 16 at 5:57 PMShareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMAprnewswire.com - February 16 at 2:25 PMKNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholdersbusinesswire.com - February 16 at 10:07 AMKNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholdersbusinesswire.com - February 16 at 9:09 AMKinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Sharefinance.yahoo.com - February 16 at 8:52 AMKinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Shareglobenewswire.com - February 16 at 8:00 AMmarketbeat.com - February 16 at 7:59 AMShort Interest in Kinnate Biopharma Inc. (NASDAQ:KNTE) Increases By 5.8%marketbeat.com - February 16 at 7:24 AMKinnate Biopharma Inc. (NASDAQ:KNTE) Receives Average Recommendation of "Hold" from Brokeragesmarketbeat.com - February 11 at 3:16 AMLeerink Partnrs Weighs in on Kinnate Biopharma Inc.'s Q3 2024 Earnings (NASDAQ:KNTE)marketbeat.com - February 8 at 7:46 AMLeerink Partnrs Comments on Kinnate Biopharma Inc.'s Q1 2024 Earnings (NASDAQ:KNTE)marketbeat.com - February 7 at 8:06 AMAnalysts Issue Forecasts for Kinnate Biopharma Inc.'s Q2 2024 Earnings (NASDAQ:KNTE)marketbeat.com - January 19 at 8:15 AMKinnate Biopharma Inc. (NASDAQ:KNTE) Forecasted to Earn Q1 2024 Earnings of ($0.41) Per Sharemarketbeat.com - January 18 at 7:31 AMWedbush Reiterates "Neutral" Rating for Kinnate Biopharma (NASDAQ:KNTE)marketbeat.com - January 17 at 8:46 AMKinnate Biopharma Inc. (NASDAQ:KNTE) Sees Large Growth in Short Interestmarketbeat.com - January 14 at 8:18 PMKinnate Biopharma: Righting The Ship, But Still Not The Right Time (Rating Upgrade)seekingalpha.com - December 12 at 7:21 AMKinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist Investorsfinance.yahoo.com - November 24 at 1:58 PMWhy is Cancer-Focused Kinnate Biopharma Stock Trading Higher Today?msn.com - November 15 at 2:53 PMOrbiMed Advisors LLC Reduces Stake in Kinnate Biopharma Incfinance.yahoo.com - November 15 at 9:52 AMKinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updatesfinance.yahoo.com - November 9 at 5:32 PMInstrument Name Kinnate Biopharma Inc Instrument Symbol (KNTE-Q)theglobeandmail.com - October 4 at 8:48 AMKinnate Biopharma (KNTE) Falls 40% in a Month: Here's Whyfinance.yahoo.com - October 3 at 2:15 PMJefferies Maintains Kinnate Biopharma (KNTE) Buy Recommendationmsn.com - September 20 at 6:25 PMBay Area biotech company Kinnate to lay off 70% of workforcemsn.com - September 19 at 7:59 PMWedbush Downgrades Kinnate Biopharma (KNTE)msn.com - September 19 at 7:59 PMWhy Is Cancer Firm Kinnate Biopharma Stock Trading Lower Today?msn.com - September 19 at 2:58 PMPiper Sandler Downgrades Kinnate Biopharma (KNTE)msn.com - September 19 at 2:58 PMAnalysts Move To Sidelines For Cancer Player Kinnate Biopharma After Restructuringmarkets.businessinsider.com - September 19 at 2:58 PMKinnate slashes workforce by 70%, shelves three drug programsmsn.com - September 18 at 11:38 PMKinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuringfinance.yahoo.com - September 18 at 6:38 PMmarketbeat.com - September 18 at 4:07 PMKinnate Biopharma (KNTE) Receives a Buy from H.C. Wainwrightmarkets.businessinsider.com - August 15 at 7:43 AM Get Kinnate Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for KNTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon Musk Secret Crypto Plot Exposed (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. KNTE Media Mentions By Week KNTE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KNTE News Sentiment▼0.000.45▲Average Medical News Sentiment KNTE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KNTE Articles This Week▼01▲KNTE Articles Average Week Get Kinnate Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for KNTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NGM Biopharmaceuticals News FibroGen News Ocuphire Pharma News LianBio News Inovio Pharmaceuticals News Avid Bioservices News Sagimet Biosciences News Vaxart News Amylyx Pharmaceuticals News Omega Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KNTE) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThis 1 Biotech Stock has been shocking the marketsHuge AlertsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kinnate Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
